Adrenoleukodystrophy (ALD) is a rare genetic condition that causes the buildup of very long-chain fatty acids (VLCFAs) in the brain. When VLCFAs accumulate, they destroy the protective myelin sheath around nerve cells, responsible for brain function. Without the myelin sheath, the nerves can no longer relay information to and from the brain. The defective gene in ALD, commonly referred to as a genetic mutation, can cause several different but related conditions: adrenomyelopathy (AMN), Addison’s disease and — the most common and most devastating form — cerebral ALD. Cerebral ALD strikes boys between ages 4 and 10, leading to permanent disability and death usually within four to eight years. There are three distinct types of X-linked adrenoleukodystrophy: a childhood cerebral form, an adrenomyeloneuropathy type, and a form called Addison disease only.
“Adrenoleukodystrophy Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenoleukodystrophy market. A detailed picture of the Adrenoleukodystrophy pipeline landscape is provided, which includes the disease overview and Adrenoleukodystrophy treatment guidelines.
Adrenoleukodystrophy of pipeline development activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Adrenoleukodystrophy with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Adrenoleukodystrophy treatment.
- Adrenoleukodystrophy key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Adrenoleukodystrophy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Request for sample pages: https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight
Scope of the report
- The Adrenoleukodystrophy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Adrenoleukodystrophy across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Adrenoleukodystrophy therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Adrenoleukodystrophy research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Adrenoleukodystrophy .
Table of contents:
1. Report Introduction
2.3. Adrenoleukodystrophy Symptoms
2.6. Adrenoleukodystrophy Diagnosis
2.6.1. Diagnostic Guidelines
3. Adrenoleukodystrophy Current Treatment Patterns
3.1. Adrenoleukodystrophy Treatment Guidelines
4. Adrenoleukodystrophy – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Adrenoleukodystrophy companies collaborations, Licensing, Acquisition -Deal Value Trends
184.108.40.206. Assessment Summary
4.1.2. Adrenoleukodystrophy Collaboration Deals
220.127.116.11. Company-Company Collaborations (Licensing / Partnering) Analysis
18.104.22.168. Company-University Collaborations (Licensing / Partnering) Analysis
22.214.171.124. Adrenoleukodystrophy Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
126.96.36.199. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
188.8.131.52. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
184.108.40.206. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
220.127.116.11. Assessment by Stage and MOA
5.1.6. Assessment by Target
18.104.22.168. Assessment by Stage and Target
6. Adrenoleukodystrophy Late Stage Products (Phase-III)
7. Adrenoleukodystrophy Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Adrenoleukodystrophy Discontinued Products
13. Adrenoleukodystrophy Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
22.214.171.124. Product Overview
126.96.36.199. Mechanism of action
13.1.2. Research and Development
188.8.131.52. Clinical Studies
13.1.3. Product Development Activities
184.108.40.206. Patent Detail
13.1.4. Tabulated Product Summary
220.127.116.11. General Description Table
Detailed information in the report?
14. Adrenoleukodystrophy Key Companies
15. Adrenoleukodystrophy Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Adrenoleukodystrophy Unmet Needs
18. Adrenoleukodystrophy Future Perspectives
19. Adrenoleukodystrophy Analyst Review
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States